



CASE  
COMPREHENSIVE  
CANCER CENTER



## San Antonio Breast Cancer Symposium

Dec 4-8, 2018

<https://www.sabcs.org/Program>

Open Sattelite Event – Thursday, December 6 7:30 pm – 10:00 pm

### Debates, Dilemmas, and Consensus: Evolving Standards of Care in HER2- Positive Breast Cancer

Moderator: Jame Abraham, MD, FACP - Director of Breast Oncology Program, Taussig Cancer Institute, Professor of Medicine, Cleveland Clinic, Cleveland, OH

Spotlight Session 1 – Wednesday, December 5 5:00 pm – 7:00 pm

#### Developmental Therapeutics

**PD1-09** Phase 2 safety and efficacy results of TAK-228 in combination with exemestane or fulvestrant in postmenopausal women with ER-positive/HER2-negative metastatic breast cancer previously treated with everolimus  
*Diamond JR, Potter D, Salkeni M, Silverman P, Haddad T, Forget F, Awada A, Canon J-L, Danso M, Lortholary A, Bourgeois H, Tan-Chiu E, Patel C, Neuwirth R, Leonard EJ, Lim B. University of Colorado Cancer Center, Aurora, CO; University of Minnesota, Minneapolis, MN; West Virginia University, Morgantown, WV; University Hospitals Cleveland Medical Center, Cleveland, OH; Mayo Clinic, Rochester, MN; Centre Hospitalier de l'Ardenne, Libramont, Belgium; Institut Jules Bordet, Université Libre de Bruxelles, Bruxelles, Belgium; Grand Hôpital de Charleroi, Charleroi, Belgium; Virginia Oncology Associates - Hampton, Chesapeake, VA; Centre Catherine de Sienne, Nantes, France; Clinique Victor Hugo - Centre Jean Bernard, Sarthe, France; Florida Cancer Research Institute, Plantation, FL; Millennium Pharmaceuticals, Inc., a Wholly Owned Subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, MA; M.D. Anderson Cancer Center, Houston, TX.*

Poster Session 1 – Wednesday, December 5 5:00 pm – 7:00 pm

#### Epidemiology, Risk, and Prevention: Ethnic/Racial Aspects

**P1-10-01** Defining the spectrum of germline variants among African American patients with triple negative breast cancer  
*Pederson HJ, Heald B, Budd GT, Bernhisel R, Cummings S, Saam JR, Lancaster JM, Grobmyer SR, Eng C. Cleveland Clinic, Cleveland, OH; Myriad Genetic Laboratories, Inc., Salt Lake City, UT.*

Spotlight Session 3 – Thursday, December 6 7:00 am – 9:00 am

#### Next Steps in HER2 Targeted Therapy

**PD3-04** Analysis of ERBB2 (HER2) amplification by ctDNA in a phase Ib dose-escalation trial evaluating trastuzumab emtansine (T-DM1) with neratinib in women with metastatic disease with initially diagnosed HER2+ breast cancer: NSABP FB-10  
*Abraham J, Puhalla SL, Sikov WM, Montero AJ, Salkeni MA, Razaq WA, Beumer JH, Kiesel BF, Buyse ME, Adamson LM, Srinivasan A, Pogue-Geile KL, Allegra CJ, Nagy RJ, Jacobs SA. NSABP Foundation, Pittsburgh; Cleveland Clinic Foundation, Cleveland; University of Pittsburgh Medical Center, Pittsburgh; Women and Infants Hospital of RI, Providence; West Virginia University, Morgantown; Peggy and Charles Stephenson Oklahoma Ca Ctr, Oklahoma City; UPMC Hillman Cancer Center, Pittsburgh; IDDI, Inc., San Francisco; NSABP/NRG Oncology, Pittsburgh; University of Florida, Gainesville; Guardant Health, Redwood City; University of Pittsburgh Cancer Institute, Univ of Pgh School of Medicine, Pittsburgh.*

## Spotlight Session 5 – Thursday, December 6 5:00 pm – 7:00 pm

### Immunotherapy

PD5-02	Durability of clinical benefit with niraparib + pembrolizumab in patients with advanced triple-negative breast cancer beyond <i>BRCA</i> : (TOPACIO/Keynote-162) <i>Vinayak S, Tolaney SM, Schwartzberg L, Mita M, McCann G, Tan AR, Wahner Hendrickson A, Forero A, Anders C, Wulf G, Dillon P, Lynce F, Zarwan C, Erban J, Färkkilä A, Zhou Y, Buerstatte N, Graham JR, Arora S, Dezube B, Telli ML. Case Comprehensive Cancer Center, University Hospitals, Case Western Reserve University, Cleveland, OH; Dana-Farber Cancer Institute, Boston, MA; The West Clinic, Memphis, TN; Cedars-Sinai Medical Center, Los Angeles, CA; University of Texas Health Science Center at San Antonio, San Antonio, TX; Levine Cancer Institute, Atrium Health, Charlotte, NC; Mayo Clinic Rochester, Rochester, MN; University of Alabama at Birmingham, Birmingham, AL; University of North Carolina Lineberger Comprehensive Cancer Center and University of North Carolina, Chapel Hill, NC; Beth Israel Deaconess Medical Center, Boston, MA; University of Virginia, Charlottesville, VA; Lombardi Comprehensive Cancer Center, MedStar Georgetown University Hospital, Washington DC; Lahey Hospital and Medical Center, Burlington, MA; Tufts Medical Center, Boston, MA; TESARO, Inc., Waltham, MA; Stanford University School of Medicine, Stanford, CA.</i>
--------	---

## Spotlight Session 8 – Friday, December 7 7:00 am – 9:00 am

### Local Regional Therapy

PD8-07	Does resection of cavity shave margins result in lower positive margin and re-excision rates in patients with stage 0-III breast cancer? Results from a prospective multicenter randomized controlled trial <i>Chagpar AB, Tsangaris T, Garcia-Cantu C, Howard-McNatt M, Chiba A, Berger AC, Levine E, Gass JS, Gallagher K, Lum SS, Martinez RD, Willis AI, Pandya SV, Brown EA, Fenton A, Mendiola A, Murray M, Haddad V, Solomon NL, Senthil M, Bansil H, Ollila D, Snyder SK, Edmonson D, Lazar M, Namm JP, Li F, Butler M, McGowan NE, Herrera ME, Avitan YP, Yoder B, Dupont E. Yale University, New Haven, CT; Thomas Jefferson University, Philadelphia, PA; Doctors Hospital at Renaissance, Edinburg, TX; Wake Forest University, Winston-Salem, NC; Women and Infants Hospital, Providence, RI; University of North Carolina, Chapel Hill, NC; Loma Linda University, Loma Linda, CA; Beaumont Hospital, Troy, MI; Cleveland Clinic Akron General, Akron, OH; Watson Clinic, Lakeland, FL; MicroPath Laboratories, Lakeland, FL.</i>
--------	--

## Poster Session 4 – Friday, December 7 7:00 am – 9:00 am

### Tumor Cell and Molecular Biology: New Drugs and Mechanisms

P4-07-06	Cyclin dependent kinase 7 (CDK7) inhibition with THZ1 induces mitotic failure and increases genomic instability in triple negative breast cancer <i>Webb BM, Sahni JM, Keri RA. Case Western Reserve University School of Medicine, Cleveland, OH; New York University School of Medicine, Cleveland, OH.</i>
----------	--

## Poster Session 5 – Friday, December 7 5:00 pm – 7:00 pm

### Tumor Cell and Molecular Biology: Drug Resistance

P5-03-01	LIN9 regulation of NEK2 underlies taxol resistance in triple-negative breast cancer <i>Shively MS, Gayle SS, Sahni JM, Keri RA. Case Western Reserve University, Cleveland, OH; New York University School of Medicine, New York, NY.</i>
----------	--

### Tumor Cell and Molecular Biology: Microenvironments - Stromal-Epithelial Interactions

P5-07-01	Computational scoring of tumor infiltrating lymphocytes in triple-negative breast cancer <i>Amgad M, Sarkar A, Srinivas C, Redman R, Ratra S, Bechert CJ, Calhoun BC, Mrazek K, Kurkure U, Cooper LA, Barnes M. Emory University School of Medicine, Atlanta, GA; Roche Tissue Diagnostics, Digital Pathology, Mountain View, CA; Roche Diagnostics Information Solutions, Belmont, CA; Robert J. Tomsich Pathology and Laboratory Medicine Institute, Cleveland Clinic, Cleveland, OH.</i>
----------	--

**Psychosocial, QOL, and Educational Aspects: Cost Effectiveness**

**P5-15-02** Evaluating the cost of endocrine therapy vs. radiation therapy alone for low risk hormone positive early stage breast cancer in elderly patients  
*Ward MC, Vicini F, Chadha M, Pierce L, Recht A, Hayman J, Thaker N, Khan A, Keisch M, Shah C. Levine Cancer Institute, Charlotte, NC; 21st Century Oncology, Farmington Hills, MI; Mt Sinai Hospital, New York, NY; University of Michigan, Ann Arbor, MI; Beth Israel Deaconess Medical Center, Boston, MA; Arizona Oncology, Tucson, AZ; Memorial Sloan Kettering Cancer Center, New York, NY; Cancer HealthCare Associates, Miami, FL; Cleveland Clinic, Cleveland, OH.*

**Treatment: DCIS/LCIS**

**P5-18-01** Risk of contralateral breast cancer (CBC) in women with ductal carcinoma in situ (DCIS) with and without and synchronous lobular carcinoma in situ (LCIS)  
*Miller ME, Muhsen S, Zabor EC, Flynn J, Olcese C, Giri D, Van Zee KJ, Pilewskie M. Case Western Reserve University, University Hospitals, Cleveland, OH; Memorial Sloan Kettering Cancer Center, New York, NY.*

**Poster Session 6 – Saturday, December 8 7:00 am – 9:00 am**

**Treatment: Novel Targets and Targeted Agents**

**P6-20-01** METRIC: A randomized international phase 2b study of the antibody-drug conjugate (ADC) glembatumumab vedotin (GV) in gpNMB-overexpressing, metastatic, triple-negative breast cancer (mTNBC)  
*Vahdat LT, Forero-Torres A, Schmid P, Blackwell K, Tellli ML, Melisko M, Holgado E, Moebus V, Cortes J, Fehrenbacher L, Montero AJ, Ma C, Nanda R, Wright GS, He Y, Bagley RG, Halim A, Turner CD, Yardley DA. Weill Cornell Medical College, New York; University of Alabama, Alabama; Barts Cancer Institute, London, United Kingdom; Duke University Medical Center, Durham; Stanford University School of Medicine, Stanford; University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco; Ramon y Cajal University Hospital, Madrid, Spain; Klinikum Frankfurt Hoechst, Frankfurt, Germany; Kaiser Permanente, Vallejo; Cleveland Clinic, Cleveland, OH; Washington University, St. Louis; University of Chicago, Chicago; Florida Cancer Specialists, New Port Richey; Celldex Therapeutics, Hampton; Sarah Cannon Research Institute/Tennessee Oncology, Nashville.*